Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Apr
02
Today In Oncology
Activity Observed With Novel KRAS Inhibitor in Pancreatic Cancer (1)
Early Results From a Trial of Active Surveillance for Low-Risk DCIS Are Reassuring Say Researchers
AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC
Machine-Learning Model for HCC Risk Prediction May Outperform Current Methods
Nivolumab With or Without Ipilimumab in Platinum-Refractory Advanced Neuroendocrine Carcinoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo